Ginseng saponin enriched in rh1 and rg2 ameliorates nonalcoholic fatty liver disease by inhibiting inflammasome activation
New FDA policy on compounding GLP-1 drugs New FDA policy on compounding GLP-1 drugs On April 24, 2025, FDA announced that licensed pharmacies and physicians can no longer compound semaglutide (a GLP-1 drug used in Ozempic & Wegovy) and outsourcing facilities must stop production by May 22, 2025
Vitamin B12 injection should be administered only under the recommendation and guidance of a medical professional and they should be aware of complete medical history including any conditions such as hypokalemia, polycythemia vera, gout, Lebers disease, iron and/or folic acid deficiency
pp 109118 Costa A, Martignoni E, Bono G, Monzani A, Nappi G